Bendroflumethiazide
Corzide, Naturetin (bendroflumethiazide) is a small molecule pharmaceutical. Bendroflumethiazide was first approved as Naturetin-2.5 on 1982-01-01. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bendroflumethiazide
Bendroflumethiazide
+
Nadolol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORZIDE | King Pharmaceuticals | N-018647 DISCN | 1983-05-25 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nadolol and bendroflumethiazide | ANDA | 2016-04-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| edema | — | D004487 | R60.9 |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| nephrotic syndrome | EFO_0004255 | D009404 | N04 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03A: Low-ceiling diuretics, thiazides
— C03AA: Thiazides, plain
— C03AA01: Bendroflumethiazide
— C03AB: Thiazides and potassium in combination
— C03AB01: Bendroflumethiazide and potassium
— C03E: Diuretics and potassium-sparing agents in combination
— C03EA: Low-ceiling diuretics and potassium-sparing agents
— C03EA13: Bendroflumethiazide and potassium-sparing agents
HCPCS
No data
Clinical
Clinical Trials
95 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 2 | 8 | 6 | 4 | 1 | 18 |
| Cerebral palsy | D002547 | G80 | 1 | 2 | 1 | 3 | — | 6 | |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 1 | 1 | 2 | 4 |
| Muscle spasticity | D009128 | HP_0001257 | — | 1 | — | 2 | — | 3 | |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | 2 | — | 3 |
| Alcohol withdrawal delirium | D000430 | EFO_1000800 | — | 1 | — | 1 | 1 | 3 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
| Hemiplegia | D006429 | G81.0 | — | — | — | 1 | — | 1 | |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 1 | — | 1 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 3 | — | — | 4 |
| Analgesia | D000698 | — | 1 | 1 | — | — | 1 | ||
| Acute pain | D059787 | R52 | — | 1 | 1 | — | — | 1 | |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | 1 | 1 | — | — | 1 |
| Leukemia | D007938 | C95 | — | — | 1 | — | — | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | — | — | 1 | — | — | 1 | |
| Neoplasms | D009369 | C80 | — | — | 1 | — | — | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | — | 1 | — | — | 1 | |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 | |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | — | 3 | — | — | — | 3 | |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | 2 | 3 |
| Cocaine-related disorders | D019970 | F14 | — | 3 | — | — | — | 3 | |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | 1 | 2 | |
| Fragile x syndrome | D005600 | Q99.2 | 1 | 1 | — | — | — | 2 | |
| Muscle cramp | D009120 | HP_0003394 | — | 1 | — | — | 1 | 2 | |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 2 | — | — | — | 2 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | — | — | — | 1 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | — | — | — | 1 | |
| Alcoholic liver cirrhosis | D008104 | EFO_1000802 | K70.3 | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | 1 | 4 | ||
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Neonatal abstinence syndrome | D009357 | EFO_0005799 | P96.1 | 1 | — | — | — | — | 1 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | — | — | — | — | 1 |
| Cheyne-stokes respiration | D002639 | R06.3 | 1 | — | — | — | — | 1 | |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | — | — | — | 1 | 1 |
| Synovitis | D013585 | EFO_0008997 | M67.5 | — | — | — | — | 1 | 1 |
| Spasm | D013035 | M62.83 | — | — | — | — | 1 | 1 | |
| Radiculopathy | D011843 | M54.1 | — | — | — | — | 1 | 1 | |
| Gout | D006073 | EFO_0004274 | M10 | — | — | — | — | 1 | 1 |
| Feeding and eating disorders | D001068 | F50 | — | — | — | — | 1 | 1 | |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BENDROFLUMETHIAZIDE |
| INN | bendroflumethiazide |
| Description | Bendroflumethiazide is a sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group. It has a role as a diuretic and an antihypertensive agent. It is a benzothiadiazine and a sulfonamide. |
| Classification | Small molecule |
| Drug class | diuretics (thiazide derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 73-48-3 |
| RxCUI | 1369 |
| ChEMBL ID | CHEMBL1684 |
| ChEBI ID | 3013 |
| PubChem CID | 2315 |
| DrugBank | DB00436 |
| UNII ID | 5Q52X6ICJI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,315 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
34,943 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more